Hester acquires technology from ICAR - IVRI to develop Brucella Abortus S19 Delta Per Vaccine

23 Sep 2020 Evaluate

Hester Biosciences has signed the agreement towards receiving the indigenously developed technology from ICAR-IVRI (Indian Council of Agriculture Research - Indian Veterinary Research Institute), for developing the Brucella Abortus S19 Delta Per vaccine.

While Hester is currently manufacturing the conventional Brucella Abortus S19 vaccine and supplying to all the states in India, the S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced safety, immunogenicity, as well as assuring lifelong immunity with a single shot in calf-hood.

The Government of India has planned to immunize 4 crore female calves in India in the first phase against Brucella through vaccination. Hester has been and commits to remain a part of the Government of India’s immunization program against Brucella in cattle. 

With this vaccine Hester hopes to reach new heights not only within India but also become a channel for immunizing cattle against Brucella, worldwide. Hester hopes to launch the Brucella Abortus S19 Delta Per vaccine in 18 months.

Hester Biosciences is engaged in the manufacturing of poultry vaccines.

Hester Biosciences Share Price

1664.10 -16.65 (-0.99%)
25-Apr-2024 12:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1497.45
Dr. Reddys Lab 5992.00
Cipla 1394.55
Zydus Lifesciences 930.00
Lupin 1593.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.